[go: up one dir, main page]

ES2180338T3 - Antagonistas del receptor de crf y metodos relacionados. - Google Patents

Antagonistas del receptor de crf y metodos relacionados.

Info

Publication number
ES2180338T3
ES2180338T3 ES99960363T ES99960363T ES2180338T3 ES 2180338 T3 ES2180338 T3 ES 2180338T3 ES 99960363 T ES99960363 T ES 99960363T ES 99960363 T ES99960363 T ES 99960363T ES 2180338 T3 ES2180338 T3 ES 2180338T3
Authority
ES
Spain
Prior art keywords
crf
related methods
crf receptor
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99960363T
Other languages
English (en)
Inventor
Mustapha Haddach
Jodie Nelson
Brian P Dyck
Zhiqiang Guo
Charles Q Huang
James R Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ES2180338T3 publication Critical patent/ES2180338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

Un compuesto que tiene la estructura siguiente: con inclusión de sus estereoisómeros, profármacos y sales farmacéuticamente aceptables, en la cual: n es 1 ó 2; A y C son cada uno independientemente nitrógeno, carbono o CH; B es nitrógeno o CR3; con las condiciones de que al menos uno de A, B y C es nitrógeno; A, B y C no son todos ellos nitrógeno; y A - B o B - C es un enlace doble; X es nitrógeno o CH; Ar es arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; R es un sustituyente opcional que, en cada caso, es independientemente alquilo, alquilidenilo, arilalquilo o heteroarilalquilo, en el cual m es 0, 1, 2 ¿ o 3 y representa el número de sustituyentes R; R1 es - C(H)0, 1(R4)(R5) o - SO2R5; R2 es hidrógeno o alquilo; R3 es hidrógeno, alquilo o haloalquilo; R4 es hidrógeno, ceto, alquilo, alquilidenilo, o halo; y R5 es un radical de la fórmula - Y - Z - R6, en la cual Y es un alcanodiílo, alcanodiílo sustituido, o un enlace directo, Z es NH, - N(R7), O, S, SO2, C(=O), C(=O)O, OC(=O), NHC(=O), C(=O)NH, NH(SO2), (SO2)NH, NR8C(=O)O, o un enlace directo; R6 es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo, o heterocicloalquilo sustituido; o R7 y R8 son iguales o diferentes y son independientemente alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo, o heterocicloalquilo sustituido; o R6 y R7, considerados junto con el átomo de nitrógeno al cual están unidos, forman un anillo heterocíclico o anillo heterocíclico sustituido; o R4 y R5, considerados juntos, forman ciclo - alquilo, cicloalquilo sustituido, cicloalquilcicloalquilo, cicloalquilcicloalquilo sustituido, cicloalquil arilo, cicloalquilarilo sustituido, cicloalquilheterociclo, o ciclo - alquilheterociclo sustituido.
ES99960363T 1998-11-12 1999-11-12 Antagonistas del receptor de crf y metodos relacionados. Expired - Lifetime ES2180338T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19107398A 1998-11-12 1998-11-12
US37083799A 1999-08-09 1999-08-09
US40136499A 1999-09-21 1999-09-21

Publications (1)

Publication Number Publication Date
ES2180338T3 true ES2180338T3 (es) 2003-02-01

Family

ID=27392849

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99960363T Expired - Lifetime ES2180338T3 (es) 1998-11-12 1999-11-12 Antagonistas del receptor de crf y metodos relacionados.

Country Status (17)

Country Link
US (1) US6514982B1 (es)
EP (1) EP1129091B1 (es)
JP (1) JP2002529465A (es)
KR (1) KR20010080990A (es)
CN (1) CN1217945C (es)
AT (1) ATE225349T1 (es)
AU (1) AU755552B2 (es)
CA (1) CA2350642A1 (es)
DE (1) DE69903333T2 (es)
DK (1) DK1129091T3 (es)
ES (1) ES2180338T3 (es)
HK (1) HK1038926B (es)
IL (1) IL142893A0 (es)
NO (1) NO20012194D0 (es)
NZ (1) NZ510955A (es)
PT (1) PT1129091E (es)
WO (1) WO2000027846A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129091B1 (en) * 1998-11-12 2002-10-02 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2001058489A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Preventives/remedies for postoperative stress
JP2003533530A (ja) 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニスト
KR20030060927A (ko) * 2000-11-03 2003-07-16 뉴로크린 바이오사이언시즈 인코퍼레이티드 Ｃｒｆ 수용체 길항제 및 이와 관련된 방법
KR100843281B1 (ko) 2000-12-28 2008-07-09 오노 야꾸힝 고교 가부시키가이샤 삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
AU2002249474B2 (en) * 2001-04-30 2006-01-12 Glaxo Group Limited Crf receptor antagonists
EP1392689B1 (en) 2001-05-21 2006-10-25 Neurocrine Biosciences, Inc. Tri- and tetraaza-acenaphthylen derivatives as crf receptor antagonists
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
AU2004249629B2 (en) 2003-06-25 2009-07-30 Ono Pharmaceutical Co., Ltd. Methanesulfonic acid salt of pyrazolopyrimidine compound, crystal thereof, and process for producing the same
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
JP2007501822A (ja) * 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー コルチコトロピン放出性因子（ｃｒｆ）アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン
EP1697362B1 (en) * 2003-12-22 2008-03-05 SB Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
IN2012DN04853A (es) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
WO2005087775A1 (ja) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
US7869958B2 (en) * 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors
AU2008211729A1 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
US8343983B2 (en) * 2009-03-31 2013-01-01 Arqule, Inc. Substituted pyrazolo-pyrimidine compounds
CA2764885C (en) * 2009-06-08 2018-05-15 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
WO2011082273A2 (en) * 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
CN113416191A (zh) * 2021-04-27 2021-09-21 西安交通大学 一种合成三环骨架2-吡啶酮/2-吡啶亚胺类化合物的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
EP0674641B1 (en) * 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
BR9307664A (pt) 1992-12-17 1999-06-29 Pfizer Pirazóis substituídos como antagonistas
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
WO1994013643A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
US6020492A (en) 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
AU725254B2 (en) 1996-03-26 2000-10-12 Du Pont Pharmaceuticals Company Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
WO1998005661A1 (en) 1996-08-06 1998-02-12 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CA2263566C (en) * 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1129091B1 (en) * 1998-11-12 2002-10-02 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto

Also Published As

Publication number Publication date
CA2350642A1 (en) 2000-05-18
IL142893A0 (en) 2002-04-21
HK1038926B (en) 2003-07-18
AU1725800A (en) 2000-05-29
DK1129091T3 (da) 2002-11-04
CN1217945C (zh) 2005-09-07
EP1129091B1 (en) 2002-10-02
NO20012194L (no) 2001-05-03
DE69903333D1 (de) 2002-11-07
EP1129091A2 (en) 2001-09-05
NZ510955A (en) 2003-01-31
KR20010080990A (ko) 2001-08-25
WO2000027846A3 (en) 2000-11-16
ATE225349T1 (de) 2002-10-15
CN1328559A (zh) 2001-12-26
WO2000027846A2 (en) 2000-05-18
NO20012194D0 (no) 2001-05-03
DE69903333T2 (de) 2003-08-07
HK1038926A1 (en) 2002-05-10
PT1129091E (pt) 2003-02-28
AU755552B2 (en) 2002-12-12
JP2002529465A (ja) 2002-09-10
US6514982B1 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
ES2180338T3 (es) Antagonistas del receptor de crf y metodos relacionados.
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
NO20012228D0 (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
AU1529402A (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
TW200626599A (en) CRF receptor antagonists and methods relating thereto
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
DE60231386D1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
BRPI0417943A (pt) antagonistas de receptor de crf e métodos relacionados para essa finalidade
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
IL158806A0 (en) Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
YU39603A (sh) Jedinjenja piperazinilpirazina kao antagonisti serotonin 5-ht2 receptora